HR1463-119

Introduced

To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to Medical Devices; Laboratory Developed Tests, and for other purposes.

119th Congress Introduced Feb 21, 2025

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

The bill provides prohibition on funding for FDA rule relating to medical devices; laboratory developed tests. It relies on appropriations. The main policy areas are Healthcare.

Who Benefits and How

FDA and related agencies could face lower compliance burdens.

Who Bears the Burden and How

No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.

Key Provisions

  • Provides prohibition on funding for FDA rule relating to medical devices; laboratory developed tests.

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

The bill provides prohibition on funding for FDA rule relating to medical devices; laboratory developed tests.

Key Policy Areas

Healthcare

Primary Purpose

The bill provides prohibition on funding for FDA rule relating to medical devices; laboratory developed tests.

Policy Domains

Healthcare

H.R. 1463 — To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to Medical Devices; Laboratory Developed Tests, and for other purposes.

Identified Gains
  • FDA and related agencies
Model: codex-gpt-5:bulk-repair | Version: bill_summary_v2 | Source: ih
FDA and related agencies:

Legislative Progress

Introduced
Introduced Committee Passed
Feb 21, 2025

Mr. Finstad (for himself and Mr. Crenshaw) introduced the following …

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Government
1 mention across 1 clause
+1 positive

FDA and related agencies

1/1
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Healthcare

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology